FORT LAUDERDALE, FL --(Marketwired - July 21, 2014) - OmniComm Systems, Inc. (
OmniComm Systems and TFS enjoy a long-standing strategic partnership providing their clients globally with exceptional services and superior functionality. The recent release of TrialMaster 4.2 was a primary reason for TFS' selection. TrialMaster includes over 300 new innovative productivity and functionality enhancements, including TrialMaster unique features like auto-redaction for faster and more efficient centralized and risked based monitoring, as well as major new automation features for exporting data utilizing OmniComm's award winning Export Utility.
Thea Wesseling, Executive Vice President, Global Clinical Development, commented, "As we continue to expand our geographic reach and services, at TFS we are always working to add value and enhance our services to our customers. We believe this collaboration will ensure we offer our customers a highly flexible EDC platform that is cost effective and extremely user-friendly. We believe our customers will really benefit from this new system's functionality and full 24/7 real-time transparency."
"Focused on growth, TFS requires a best-in-class solution that will extend its clinical data management and EDC capabilities," said Dr. Kuno van der Post, senior vice president business development, OmniComm Systems, Inc. "TFS selected TrialMaster as its core EDC solution to enable rapid trial set up, data accuracy, and clinical trial productivity enabling TFS to gain the trust of both local and global trial sponsors. We are glad to welcome TFS to the growing CRO community adapting TrialMaster as their core EDC solution."
TFS contracted OmniComm's Professional Services proven QuickStart™ implementation methodology taking advantage of OmniComm's project management, training, QA support and extensive transformation implementing services, along with validation kits that accelerate study setup time and reduce overall cost. A growing number of eClinical Suite customers are moving to TrialMaster with the assistance of OmniComm's Professional and Transformation Services teams. OmniComm takes pride in the fact their implementations are based on standard, proven and trusted business processes that reduce implementation time and cost. TFS will also utilize OmniComm's CDASH library of clinical case report forms (CRFs).
Supporting Information
About OmniComm Systems OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world's pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com .
About TFS International TFS International is the largest privately owned clinical Contract Research Organization (CRO). Founded in 1996 in Sweden, TFS currently operates in 20 countries throughout Europe, USA and Japan and employs approximately 650 clinical research professionals. TFS supports multiple therapeutic areas and provides services worldwide through four business areas: TFS Explore™ (Early Phase Clinical Trials, Phase I-IIa), TFS Develop™ (Full service clinical programs, Phase II-IV and NIS), TFS People™ (Functional Insourcing Solutions), and TFS Academy™ (Specialist training for clinical research professionals). For detailed information about TFS, its business offerings, global locations and recent press releases, please visit www.tfscro.com .
Safe Harbor Disclaimer Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Trademarks OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
